Infusing biologic agents, such as infliximab and vedolizumab, for the treatment of IBD in a patient's home is becoming increasingly common. Smaller studies have raised concern about the safety of infusing biologic agents at home. However, the large-scale national experience with safety of home infusions has not been reported. Additionally, the patient experience with home infusions is unknown. Therefore, we conducted a mixed-methods study to better understand home infusions of infliximab and vedolizumab for patients with IBD.

We studied whether patients starting Entyvio® (vedolizumab), who had previously used an anti-TNF biologic, such as Remicade® (infliximab) or Humira® (adalimumab), responded differently than people who had not used one of these therapies. We studied 380 patients with Crohn's disease and ulcerative colitis in the IBD Partners cohort who were starting vedolizumab. We found that patients who had not previously used an anti-TNF biologic had higher remission rates and improved quality of life.